Anti-ganglioside antibodies are removed from circulation in mice by neuronal endocytosis

Brain

Volumn 139, Issue 6, 2016, Pages 1657-1665

  Cunningham, Madeleine E ^a   McGonigal, Rhona ^a   Meehan, Gavin R ^a   Barrie, Jennifer A ^a   Yao, Denggao ^a   Halstead, Susan K ^a   Willison, Hugh J ^a  

^a Institute of Infection   (United Kingdom)

Author keywords

Anti ganglioside antibody; Endocytosis; Motor nerve terminal; Neuropathy, autoantibody

Indexed keywords

GANGLIOSIDE ANTIBODY; ANTIBODY; GANGLIOSIDE; N ACETYLGALACTOSAMINYLTRANSFERASE; POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; CELL BODY; CELL MEMBRANE; CONTROLLED STUDY; ENDOCYTOSIS; ENZYME ACTIVITY; EX VIVO STUDY; FEMALE; HUMAN; IN VIVO STUDY; INTERNALIZATION; MALE; MOTOR END PLATE; MOUSE; NERVE CELL; NERVE ENDING; NEUROMUSCULAR JUNCTION; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; SPINAL CORD; SYSTEMIC CIRCULATION; ANIMAL; BLOOD; DISEASE MODEL; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM;

ANIMALS; ANTIBODIES; CELL MEMBRANE; DISEASE MODELS, ANIMAL; ENDOCYTOSIS; FEMALE; GANGLIOSIDES; MALE; MICE; MICE, KNOCKOUT; N-ACETYLGALACTOSAMINYLTRANSFERASES; NEUROMUSCULAR JUNCTION; PRESYNAPTIC TERMINALS;

EID: 84976897751     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aww056     Document Type: Article

References (31)

1. Boffey J, Odaka M, Nicoll D, Wagner ER, Townson K, Bowes T, et al. Characterisation of the immunoglobulin variable region gene usage encoding the murine anti-ganglioside antibody repertoire. J Neuroimmunol 2005; 165: 92-103.
2. Bowes T, Wagner ER, Boffey J, Nicholl D, Cochrane L, Benboubetra M, et al. Tolerance to self gangliosides is the major factor restricting the antibody response to lipopolysaccharide core oligosaccharides in Campylobacter jejuni strains associated with Guillain-Barre syndrome. Infect Immun 2002; 70: 5008-18.
3. Fabian RH. Uptake of plasma IgG by CNS motoneurons: comparison of antineuronal and normal IgG. Neurology 1988; 38: 1775-80.
4. Feng G, Mellor RH, Bernstein M, Keller-Peck C, Nguyen QT, Wallace M, et al. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron 2000; 28: 41-51.
5. Fewou SN, Plomp JJ, Willison HJ. The pre-synaptic motor nerve terminal as a site for antibody-mediated neurotoxicity in autoimmune neuropathies and synaptopathies. J Anat 2014; 224: 36-44.
6. Fewou SN, Rupp A, Nickolay LE, Carrick K, Greenshields KN, Pediani J, et al. Anti-ganglioside antibody internalization attenuates motor nerve terminal injury in a mouse model of acute motor axonal neuropathy. J Clin Invest 2012; 122: 1037-51.
7. Galban-Horcajo F, Halstead SK, McGonigal R, Willison HJ. The application of glycosphingolipid arrays to autoantibody detection in neuroimmunological disorders. Curr Opin Chem Biol 2014; 18: 78-86.
8. Greenshields KN, Halstead SK, Zitman FM, Rinaldi S, Brennan KM, O'Leary C, et al. The neuropathic potential of anti-GM1 autoantibodies is regulated by the local glycolipid environment in mice. J Clin Invest 2009; 119: 595-610.
9. Halstead SK, Zitman FM, Humphreys PD, Greenshields K, Verschuuren JJ, Jacobs BC, et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain 2008; 131: 1197-208.
10. Hoshino T, Mahmood MI, Mori K, Matsuzaki K. Binding and aggregation mechanism of amyloid beta-peptides onto the GM1 ganglioside-containing lipid membrane. J Phys Chem B 2013; 117: 8085-94.
11. Kuwabara S, Ogawara K, Koga M, Mori M, Hattori T, Yuki N. Hyperreflexia in Guillain-Barre syndrome: relation with acute motor axonal neuropathy and anti-GM1 antibody. J Neurol Neurosurg Psychiatry 1999; 67: 180-4.
12. Lunn MP, Johnson LA, Fromholt SE, Itonori S, Huang J, Vyas AA, et al. High-affinity anti-ganglioside IgG antibodies raised in complex ganglioside knockout mice: reexamination of GD1a immunolocalization. J Neurochem 2000; 75: 404-12.
13. McGonigal R, Rowan EG, Greenshields KN, Halstead SK, Humphreys PD, Rother RP, et al. Anti-GD1a antibodies activate complement and calpain to injure distal motor nodes of Ranvier in mice. Brain 2010; 133: 1944-60.
14. Nores GA, Lardone RD, Comin R, Alaniz ME, Moyano AL, Irazoqui FJ. Anti-GM1 antibodies as a model of the immune response to selfglycans. Biochim Biophys Acta 2008; 1780: 538-45.
15. Plomp JJ, Willison HJ. Pathophysiological actions of neuropathyrelated anti-ganglioside antibodies at the neuromuscular junction. J Physiol 2009; 587: 3979-99.
16. Rinaldi S, Brennan KM, Goodyear CS, O'Leary C, Schiavo G, Crocker PR, et al. Analysis of lectin binding to glycolipid complexes using combinatorial glycoarrays. Glycobiology 2009; 19: 789-96.
17. Ritchie TC, Fabian RH, Choate JV, Coulter JD. Axonal transport of monoclonal antibodies. J Neurosci 1986; 6: 1177-84.
18. Rummel A. Double receptor anchorage of botulinum neurotoxins accounts for their exquisite neurospecificity. Curr Top Microbiol Immunol 2013; 364: 61-90.
19. Sacino AN, Brooks M, Thomas MA, McKinney AB, Lee S, Regenhardt RW, et al. Intramuscular injection of alpha-synuclein induces CNS alpha-synuclein pathology and a rapid-onset motor phenotype in transgenic mice. Proc Natl Acad Sci USA 2014; 111: 10732-7.
20. Schengrund CL. Gangliosides: glycosphingolipids essential for normal neural development and function. Trends Biochem Sci 2015; 40: 397-406.
21. Shahrizaila N, Yuki N. Bickerstaff brainstem encephalitis and Fisher syndrome: anti-GQ1b antibody syndrome. J Neurol Neurosurg Psychiatry 2013; 84: 576-83.
22. Stoeckel K, Schwab M, Thoenen H. Role of gangliosides in the uptake and retrograde axonal transport of cholera and tetanus toxin as compared to nerve growth factor and wheat germ agglutinin. Brain Res 1977; 132: 273-85.
23. Takamiya K, Yamamoto A, Furukawa K, Yamashiro S, Shin M, Okada M, et al. Mice with disrupted GM2/GD2 synthase gene lack complex gangliosides but exhibit only subtle defects in their nervous system. Proc Natl Acad Sci USA 1996; 93: 10662-7.
24. van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain-Barre syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol 2014; 10: 469-82.
25. Wenthold RJ, Skaggs KK, Reale RR. Retrograde axonal transport of antibodies to synaptic membrane components. Brain Res 1984; 304: 162-5.
26. Wootla B, Watzlawik JO, Warrington AE, Wittenberg NJ, Denic A, Xu X, et al. Naturally occurring monoclonal antibodies and their therapeutic potential for neurologic diseases. JAMA Neurol 2015; 72: 1346-53.
27. Xu X, Denic A, Jordan LR, Wittenberg NJ, Warrington AE, Wootla B, et al. A natural human IgM that binds to gangliosides is therapeutic in murine models of amyotrophic lateral sclerosis. Dis Model Mech 2015; 8: 831-42.
28. Yao D, McGonigal R, Barrie JA, Cappell J, Cunningham ME, Meehan GR, et al. Neuronal expression of GalNAc transferase is sufficient to prevent the age-related neurodegenerative phenotype of complex ganglioside-deficient mice. J Neurosci 2014; 34: 880-91.
29. Yuki N, Kokubun N, Kuwabara S, Sekiguchi Y, Ito M, Odaka M, et al. Guillain-Barre syndrome associated with normal or exaggerated tendon reflexes. J Neurol 2012; 259: 1181-90.
30. Zuckier LS, Rodriguez LD, Scharff MD. Immunologic and pharmacologic concepts of monoclonal antibodies. Semin Nucl Med 1989; 19: 166-86.
31. Zuo Y, Lubischer JL, Kang H, Tian L, Mikesh M, Marks A, et al. Fluorescent proteins expressed in mouse transgenic lines mark subsets of glia, neurons, macrophages, and dendritic cells for vital examination. J Neurosci 2004; 24: 10999-1009.